Search research articles
Contact Us
Filters
Showing results (61-70 of 333) with videos related to
Page
of 34
Sort By:
Pharmacoeconomics
|
January 14, 2010
Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US
John F P Bridges, Eberechukwu Onukwugha, C Daniel Mullins
Clinical Therapeutics
|
May 17, 2003
Factors associated with hospitalization costs for patients with community-acquired pneumonia
Sanjay Merchant, C Daniel Mullins, Ya-Chen Tina Shih
The American Journal of Managed Care
|
June 30, 2011
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer
Michael Grabner, Eberechukwu Onukwugha, Rahul Jain, et al.
Archives of Pediatrics & Adolescent Medicine
|
April 7, 2010
Cost-effectiveness of a motivational intervention to reduce rapid repeated childbearing in high-risk adolescent mothers: a rebirth of economic and policy considerations
Beth Barnet, Thomas Rapp, Margo DeVoe, et al.
Pharmacoeconomics
|
September 1, 2006
Cost-of-illness studies : a review of current methods
Ebere Akobundu, Jing Ju, Lisa Blatt, et al.
Journal of Comparative Effectiveness Research
|
October 30, 2020
Six ways to foster community-engaged research during times of societal crises
Hillary A Edwards, Dwyan Y Monroe, C Daniel Mullins
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 5, 2024
Quality-Adjusted Life Years, Quality-Adjusted Life-Year-Like Measures, or Neither? The Debate Continues
Nancy J Devlin, Michael F Drummond, C Daniel Mullins
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 10, 2002
Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible?
C Daniel Mullins, Betina T Blak, Kasem S Akhras
Research in Social & Administrative Pharmacy : RSAP
|
July 8, 2011
Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings
Rahul Jain, C Daniel Mullins, Helen Lee, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 8, 2009
Threshold denial rates in prior authorization prescription programs
William C Grant, David M Yoder, C Daniel Mullins
Page
of 34
Search research articles
Search
Showing results (61-70 of 333) with videos related to
Sort By:
Page
of 34
Pharmacoeconomics
|
January 14, 2010
Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US
John F P Bridges, Eberechukwu Onukwugha, C Daniel Mullins
Clinical Therapeutics
|
May 17, 2003
Factors associated with hospitalization costs for patients with community-acquired pneumonia
Sanjay Merchant, C Daniel Mullins, Ya-Chen Tina Shih
The American Journal of Managed Care
|
June 30, 2011
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer
Michael Grabner, Eberechukwu Onukwugha, Rahul Jain, et al.
Archives of Pediatrics & Adolescent Medicine
|
April 7, 2010
Cost-effectiveness of a motivational intervention to reduce rapid repeated childbearing in high-risk adolescent mothers: a rebirth of economic and policy considerations
Beth Barnet, Thomas Rapp, Margo DeVoe, et al.
Pharmacoeconomics
|
September 1, 2006
Cost-of-illness studies : a review of current methods
Ebere Akobundu, Jing Ju, Lisa Blatt, et al.
Journal of Comparative Effectiveness Research
|
October 30, 2020
Six ways to foster community-engaged research during times of societal crises
Hillary A Edwards, Dwyan Y Monroe, C Daniel Mullins
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 5, 2024
Quality-Adjusted Life Years, Quality-Adjusted Life-Year-Like Measures, or Neither? The Debate Continues
Nancy J Devlin, Michael F Drummond, C Daniel Mullins
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 10, 2002
Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible?
C Daniel Mullins, Betina T Blak, Kasem S Akhras
Research in Social & Administrative Pharmacy : RSAP
|
July 8, 2011
Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings
Rahul Jain, C Daniel Mullins, Helen Lee, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 8, 2009
Threshold denial rates in prior authorization prescription programs
William C Grant, David M Yoder, C Daniel Mullins
Page
of 34